Neurofeedback as one of the Therapeutic Modalities for Generalized Anxiety Disorder

Generalized anxiety disorder (GAD) is one of the most common and disabling psychiatric conditions globally, affecting around 3-6% of the population and causing significant difficulties across psychological, occupational, and social domains. Although established first-line treatments are available, including cognitive-behavioral therapy and pharmacotherapy with selective serotonin reuptake inhibitors, many individuals with GAD either cannot access adequate care or do not respond sufficiently to conventional treatments. This treatment gap, combined with the limitations of existing approaches such as the risk of relapse after stopping medication and difficulties accessing psychotherapy, has led to growing interest in alternative interventions that target the neurobiological basis of anxiety more directly. This thesis examines neurofeedback as a treatment option for GAD, comparing it to established therapies and evaluating its mechanisms, clinical evidence, and future potential. First, it overviews anxiety disorders and their neurobiological features, then it reviews psychotherapeutic and pharmacological approaches, discussing how they work, their effectiveness, and limitations. A structured comparison, developed by synthesizing findings from the preceding chapters rather than drawn from any single source, evaluates all three approaches across key dimensions, including speed of effect, long-term outcomes, relapse risk, side effects, and accessibility. In conclusion, while neurofeedback does not yet meet the standards required for first-line treatment, it represents a distinct and promising complementary intervention that targets the neuropsychological aspects of GAD in ways that conventional treatments do not. Realizing its clinical potential will require large-scale randomized controlled trials, standardized protocols, and further investigation of its role within combined treatment approaches. This thesis examines neurofeedback as a treatment option for GAD, comparing it to established therapies and evaluating its mechanisms, clinical evidence, and future potential. First it overviews anxiety disorders and their neurobiological features, then it reviews psychotherapeutic and pharmacological approaches, discussing how they work, their effectiveness, and limitations. It then introduces neurofeedback, a non-invasive intervention based on the principles of operant conditioning and neuroplasticity, and assesses its protocols and emerging evidence. A structured comparison evaluates all three approaches across key dimensions, including speed of effect, long-term outcomes, relapse risk, side effects, and accessibility. In conclusion, while neurofeedback does not yet meet the standards required for first-line treatment, it represents a distinct and promising complementary intervention that targets the neuropsychological aspects of GAD in ways that conventional treatments do not. Realizing its clinical potential will require large-scale randomized controlled trials, standardized protocols, and further investigation of its role within combined treatment approaches.